Ampio Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative therapies for common yet difficult-to-treat medical conditions. The company's corporate philosophy revolves around delivering affordable and accessible medical treatments to patients in need. Ampio Pharmaceuticals Inc values scientific expertise, ethical practices, and a commitment to improving patient outcomes. With a dedication to research and development, Ampio Pharmaceuticals Inc strives to address unmet medical needs and enhance the quality of life for individuals worldwide.

Ampio Pharmaceuticals Inc primarily operates in the United States.

Ampio Pharmaceuticals Inc has achieved several significant milestones. One of the notable accomplishments is the successful completion of clinical trials for their lead drug candidate, Ampion™. This innovative formulation has shown promising results in treating various inflammatory conditions. Additionally, Ampio Pharmaceuticals Inc has secured multiple strategic partnerships and collaborations to further advance their research and development efforts. Their commitment to innovation and dedication to improving patient outcomes have positioned the company as a key player in the biopharmaceutical industry. As Ampio Pharmaceuticals Inc continues to progress, they are actively focused on expanding their portfolio of therapies and delivering groundbreaking solutions to address unmet medical needs.

Ampio Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development of novel therapies for prevalent medical conditions. Established in [year], Ampio has documented an impressive history of advancements in the field of pharmaceutical research. With a focus on targeted therapies and innovative drug formulations, the company has played a pivotal role in revolutionizing treatment options for various diseases. Ampio Pharmaceuticals Inc prioritizes the development of therapies that address unmet medical needs, aiming to improve patients' quality of life and overall well-being. Building on its strong research capabilities and dedication to innovation, Ampio continues to make significant contributions to the pharmaceutical industry.

Ampio Pharmaceuticals Inc faces competition from various players in the market, including companies such as Celgene Corporation, Pfizer Inc, Johnson & Johnson, and Bristol Myers Squibb Company.

Ampio Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Ampio Pharmaceuticals Inc is focused on developing and commercializing therapies to treat prevalent inflammatory conditions. Ampio's primary focus is on developing anti-inflammatory drugs for the treatment of osteoarthritis and diabetic macular edema. The company utilizes its proprietary drug delivery technologies to enhance the efficacy of therapies and improve patient outcomes. Ampio's commitment to research and development, along with strategic partnerships and collaborations, helps drive its mission of improving the lives of patients suffering from inflammatory diseases.

P/E odnos Ampio Pharmaceuticals iznosi -0,01.

KUV kompanije Ampio Pharmaceuticals iznosi 0.

AlleAktien kvalitativni skor za Ampio Pharmaceuticals je 2/10.

Prihod trenutno ne može biti izračunat za Ampio Pharmaceuticals.

Dobit očekivana Ampio Pharmaceuticals je -139.536,00 USD.

Ampio Pharmaceuticals Inc. is an American biopharmaceutical company specializing in the development of drugs for the treatment of osteoarthritic, inflammatory, and metabolic diseases. The company is headquartered in Englewood, Colorado, and has been listed on the NYSE MKT exchange since 2010. Ampio Pharmaceuticals' business model includes a wide range of products and services aimed at improving the health and well-being of patients. The company has three main divisions: Human Therapeutics, Diagnostic Services, and Animal Health. Under the Human Therapeutics category, Ampio Pharmaceuticals offers various types of drugs for the treatment of arthritis, diabetic retinopathy, and other diseases. One of the company's most well-known products is Ampion, a biologically activated protein with anti-inflammatory and regenerative properties. It is used for the treatment of knee osteoarthritis and has been approved by the FDA for a Phase III clinical trial. In the Diagnostic Services division, Ampio Pharmaceuticals provides various tests for early disease diagnosis. The company has developed a proprietary technology platform for biomarker discovery to facilitate the diagnosis of early stages of cancer and other diseases. Ampio Pharmaceuticals also has a division focused on animal treatment. It offers specialized products to help relieve pain and inflammation in animals. Ampio is currently one of the few companies offering joint and soft tissue treatments for horses. The business model of Ampio Pharmaceuticals is based on continuous research and development of new products, enabling the company to remain competitive in a rapidly changing market. The company collaborates closely with leading medical research institutions and universities to ensure it keeps up with the latest developments in the field. Ampio Pharmaceuticals has also formed international partnerships to distribute its products globally. The company has licensed its products to many global companies for distribution in various countries. Overall, Ampio Pharmaceuticals has a solid business model based on scientific research and a focus on improving patient health. The company is committed to taking a leadership position in the biopharmaceutical industry worldwide by continuously growing and expanding its product portfolio to meet the changing needs of patients.

Ampio Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Ampio Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Ampio Pharmaceuticals je US03209T1097.

WKN od Ampio Pharmaceuticals je A1JGFU.

Oznaka za praćenje akcija kompanije Ampio Pharmaceuticals je AMPE.

U poslednjih 12 meseci, Ampio Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Ampio Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Ampio Pharmaceuticals trenutno iznosi .

Ampio Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Ampio Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Ampio Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Ampio Pharmaceuticals od 9. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 9. 9. 2024..

Isplata poslednje dividende izvršena je 9. 9. 2024..

U godini 2023 kompanija Ampio Pharmaceuticals je isplatila 0 USD kao dividende.

Dividende od Ampio Pharmaceuticals se isplaćuju u USD.